HSP90AA1 and neoplasm: To overcome this problem, small molecule inhibitors have been designed that will selectively accumulate in the mitochondria of tumour cells and target the Hsp90/TRAP1 of these organelles (e.g., shepherdin, a peptidomimetic inhibitor of the interaction between Hsp90 and its survivin client; and gamitrinibs, linking 17-AAG to lipophilic cations that act as mitochondrial targeting moieties) [6].